Аннотация

Норасоии музмини дил бо нигоҳдоштани фраксияи партоиш (НМДбФП) яке аз шаклҳои маъмултарини норасоии дил дар пиронсолон мебошад. Дар шароити пиршавии глобалии аҳолӣ аҳамияти ин беморӣ, хусусан дар беморони пиронсол ва дарозумр (≥90 сол), ки ба табобати статсионарӣ ниез доранд, меафзояд. Аммо беморони калонсол аз аксари тадқиқотҳои калони тасодуфӣ хориҷ карда шуданд, ки ин ба норасоии далелҳо барои ин категорияи беморон оварда мерасонад. Истифодаи эмпаглифлозин ва дапаглифлозин коҳиши назарраси хатари бистарӣ шудан аз сабаби норасоии дил (НД) ва беҳтар шудани пешгӯиро, новобаста аз мавҷудияти диабети қанд (ДҚ), нишон дод. Аммо, ин ТКТ-ҳо беморони аз 90-сола болоро дар бар намегирифтанд, ки ин паҳншавии мустақими натиҷаҳои онҳоро барои аҳолии дарозумр душвор мегардонд. Ҳамин тариқ, зарурати таҳлили мунтазами маълумоти муосир дар бораи самаранокӣ ва бехатарии ИКНГН2 дар одамони калонсол нигоҳ дошта мешавад, ки имкон медиҳад, ки табобат оптимизатсия карда шавад ва пешгӯиҳо бо назардошти хусусиятҳои гериатрии беморон беҳтар карда шаванд.
 

Калимаҳои калидӣ

норасоии музмини дил бо нигоҳдоштаНИ фраксияи партоИШ (НМДбФП) беморони калонсол дарозумр ингибиторҳои котранспортери натрий-глюкозаи навъи 2 (ИНГЛТ2) эмпаглифлозин дапаглифлозин самаранокӣ бехатарӣ гериатрия тадқиқоти клиникии тасодуфӣ (ТКТ).

Матни пурра

Боргирӣ кардани мақола дар PDF

Версияи пурраи мақола дар формати PDF

Феҳристи манбаъ

  1. Abdelmasih R, Thakker R, Faluk M, Alsamman MM, Hasan SM. Update on the cardiovascular benefits of Sodium-Glucose Co-Transporter-2 inhibitors: mechanism of action, available agents and comprehensive review of literature. Cardiol Res. 2021;12:210–8. DOI: 10.14740/cr1268
  2. Albulushi A, Tanoh DB, Almustafa A, Al Matrooshi N, Zolty R, Lowes BD. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis. Cardiovascular Diabetology. 2024;23(1):324. DOI: 10.1186/s12933-024-02415-8.
  3. Aguiar-Neves I, Santos-Ferreira D, Fontes-Carvalho R. SGLT2 inhibition in heart failure with preserved ejection fraction – the new frontier. Reviews in Cardiovascular Medicine. 2023;24(1):1. DOI: 10.31083/j.rcm2401001.
  4. Campbell P, Rutten FH, Lee MMY, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. The Lancet. 2024;403(10431):1083–1092. DOI: 10.1016/S0140-6736(23)02756-3.
  5. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761–72. DOI: 10.1038/s41569-020-0406-8
  6. Cappetta D, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Micciche A. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol. Res. 2020;157:104781. DOI: 10.1016/j.phrs.2020.104781
  7. Coats AJ, Butler J, Tsutsui H, Doehner W, Filippatos G, Ferreira JP. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‑Preserved. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(1):412–424. DOI: 10.1002/jcsm.13393
  8. Elkammash A, Tam SSC, Yogarajah G, You J. Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. Cureus. 2023;15(2):e35030. DOI:10.7759/cureus.35030
  9. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:312–324. DOI: 10.1016/j.jchf.2015.10.007
  10. Hamid AK, Tayem AA, Al-Aish ST, Al Sakini AS, Hadi DD, Al-Aish RT. Empagliflozin and other SGLT2 inhibitors in patients with heart failure with preserved ejection fraction: a meta-analysis. Therapeutic Advances in Cardiovascular Disease. 2024;18:17539447241289067. DOI: 10.1177/17539447241289067.
  11. Jaiswal A. SGLT2 inhibitors in HFpEF: meta-analysis of RCTs. Medicine. 2023;102(39):e34693. DOI: 10.1097/MD.0000000000034693
  12. Kolijn D, Pabel S, Tian Y, Lodi M, Herwig M, Carrizzo A, Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation. Cardiovasc. Res. 2021;117:495–507. DOI: 10.1093/cvr/cvaa123
  13. Maraey A, Salem M, Dawoud N, Khalil M, Elzanaty A, Elsharnoby H, Younes A, Hashim A, Alam A, Predictors of thirty-day readmission in nonagenarians presenting with acute heart failure with preserved ejection fraction: a nationwide analysis. Journal of Geriatric Cardiology. 2021;18(12):1008–1018. DOI: 10.11909/j.issn.1671-5411.2021.12.005.
  14. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie M.R, Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J. Am. Coll. Cardiol. 2014;64(21):2281–2293. DOI: 10.1016/j.jacc.2014.08.036
  15. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. DOI: 10.1056/NEJMoa1911303
  16. Mentz RJ, Brunton SA, Rangaswami J. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Cardiovascular Diabetology. 2023;22(1):316. DOI: 10.1186/s12933-023-02023-y
  17. Neuen BL, Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a systematic review and meta-analysis. Cardiovascular Diabetology. 2022;21(1):47. DOI: 10.1186/s12933-022-01476-x
  18. Pabel S, Hamdani N, Singh J, Sossalla S. Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction. Frontiers in Physiology. 2021;12:752370. DOI: 10.3389/fphys.2021.752370.
  19. Pabel S, Hamdani N, Sossalla S. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'. Eur. J. Heart Fail. 2020;23:841. DOI: 10.1002/ejhf.2091
  20. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
  21. Pabel S, Hamdani N, Singh J, Sossalla S. Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction. Frontiers in Physiology. 2022;13:928232. DOI: 10.3389/fphys.2022.928232
  22. Patel RN, Sharma A, Prasad A, Bansal S. Heart failure with preserved ejection fraction with chronic kidney disease: a narrative review of a multispecialty disorder. Kidney Med. 2023;5(12):100705. DOI: 10.1016/j.xkme.2023.100705
  23. Philippaert K, Kalyaanamoorthy S, Fatehi M., Long W, Soni S, Byrne NJ. Cardiac late sodium channel current is a molecular target for the Sodium/Glucose Cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143:2188–2204. DOI: 10.1161/CIRCULATIONAHA.121.053350
  24. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology. 2022;19(2):100–116. DOI: 10.1038/s41569-021-00605-5.
  25. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2022;387(12):1089–1098. DOI: 10.1056/NEJMoa2206286.
  26. Tong D. SGLT2 inhibitors in patients with HFpEF: how old is too old? Journal of Cardiovascular Aging. 2022;2:41. DOI: 10.20517/jca.2022.30.
  27. Varnado S, Ryoo Ali H-J, Trachtenberg B. Medical therapy for heart failure with preserved ejection fraction. Methodist DeBakey Cardiovascular Journal. 2022;18(5):17–26. DOI: 10.14797/mdcvj.1162.
  28. Wintrich J, Abdin A, Böhm M. Management strategies in heart failure with preserved ejection fraction. Herz. 2022;47(4):332–339. DOI: 10.1007/s00059-022-05119-5.
  29. Zhou Hufang. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in cardiovascular medicine. 2022;9:875327. DOI:10.3389/fcvm.2022.875327